J. Witek

发表

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.

M. Colombo, X. Forns, F. Nevens, 2016, Annals of hepatology.

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two‐way crossover trial

H. Crauwels, T. Kakuda, R. Hoetelmans, 2014, Journal of clinical pharmacology.

Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus, and Influenza-Related Hospitalizations in Adults—A Global Study During the 2017–2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study)

E. Walsh, A. Falsey, G. Ispas, 2021, Open forum infectious diseases.

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

E. Yoshida, G. de la Rosa, E. Lawitz, 2016, Hepatology.

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

E. Schiff, P. Kwo, D. Bernstein, 2016, Hepatology.

Pharmacokinetic Interaction between Telaprevir and Methadone

V. Garg, J. Snoeys, P. Verboven, 2013, Antimicrobial Agents and Chemotherapy.

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

G. D'offizi, M. Schlag, C. Taibi, 2017, The new microbiologica.

IL-15 enhances survival and function of HIV-specific CD8+ T cells.

J. Altman, P. Katsikis, A. Kim, 2003, Blood.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Tara L. Kieffer, C. Sarrazin, L. Gritz, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Simeprevir plus peginterferon/ribavirin for HCV genotype 1‐infected treatment‐naïve patients in China and South Korea

Ju-Hyun Kim, J. Heo, S. Ouwerkerk-Mahadevan, 2016, Journal of gastroenterology and hepatology.

Steady‐State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in Healthy HIV‐Negative Volunteers

V. Vyncke, K. Spittaels, M. Schöller-Gyüre, 2013, Journal of clinical pharmacology.

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials

P. Cahn, N. Clumeck, J. Molina, 2010, International journal of STD & AIDS.

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.

B. Clotet, C. Katlama, N. Clumeck, 2010, The Journal of antimicrobial chemotherapy.

Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.

J. Mrus, D. Jayaweera, S. Hodder, 2012, AIDS research and human retroviruses.

Pharmacokinetics and Short‐Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV‐Negative Volunteers

V. Vyncke, T. Kakuda, G. Smedt, 2013, Journal of clinical pharmacology.

Pharmacokinetic Parameters of Once-Daily Rilpivirine following Administration of Efavirenz in Healthy Subjects

H. Crauwels, J. Vingerhoets, R. Ryan, 2012, Antiviral therapy.

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.

S. Zeuzem, J. Mrus, R. Demasi, 2014, Journal of hepatology.

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment

S. Ouwerkerk-Mahadevan, A. Halabi, Indra Aerts, 2015, Journal of clinical pharmacology.

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

C. Sarrazin, M. Peeters, O. Lenz, 2015, Antiviral research.

T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219)

S. Zeuzem, C. Sarrazin, D. Bartels, 2012 .

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

M. Buti, S. Zeuzem, M. Rizzetto, 2014, Gastroenterology.

Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy

M. Buti, S. Zeuzem, J. Drenth, 2016, Antiviral therapy.

Pharmacokinetic Interaction Between Telaprevir and 1 Methadone 2 3

P. Verboven, R. Heeswijk, E. Paepe, 2013 .

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

J Witek, Julio Michael Stern, R. Pomerantz, 1999, JAMA.

Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study

M. Peeters, O. Lenz, T. Verbinnen, 2017, Journal of viral hepatitis.

IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells.

P. Katsikis, Y. Mueller, J. Witek, 2003, International immunology.

HIV-Specific CD8+ T Cells Exhibit Markedly Reduced Levels of Bcl-2 and Bcl-xL1

J. Altman, K. Mounzer, P. Katsikis, 2004, The Journal of Immunology.

LReduced Levels of Bcl-2 and Bcl-x T Cells Exhibit Markedly + HIV-Specific CD 8

J. Altman, K. Mounzer, P. Katsikis, 2004 .

Incidence of virological failure and emergence of resistance with twice‐daily vs every 8‐h administration of telaprevir in the OPTIMIZE study

M. Buti, G. Picchio, I. Dierynck, 2014, Journal of viral hepatitis.

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin

J. Aerssens, V. van Eygen, O. Lenz, 2016, Open forum infectious diseases.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

R. Haubrich, B. Clotet, C. Katlama, 2010, Antiviral therapy.

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Mark M. Davis, E. Schiff, P. Kwo, 2015 .

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

E. Yoshida, E. Lawitz, M. Peeters, 2015 .

Safety and pharmacokinetics of etravirine in pregnant HIV‐1‐infected women *

P. Izurieta, J. Witek, T. Kakuda, 2011, HIV medicine.

OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients

M. Buti, S. Zeuzem, M. Rizzetto, 2013 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells.

J. Altman, M. Roederer, S. D. De Rosa, 2001, Immunity.

T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study

T. Berg, S. Roberts, S. Zeuzem, 2012 .

Pharmacokinetics of once-daily Etravirine without and with Once-daily Darunavir/ritonavir in Antiretroviral-Naive HIV type-1-Infected Adults

P. Ruane, J. Lalezari, T. Kakuda, 2010, Antiviral therapy.

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)

H. Fennema, D. Heerwegh, W. Van der Elst, 2022, Influenza and other respiratory viruses.

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis

A. Horban, S. Ouwerkerk-Mahadevan, J. Sasadeusz, 2014, Journal of the International AIDS Society.

An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTime HCV RNA Assay

M. Buti, C. Sarrazin, G. Cloherty, 2015, Journal of Clinical Microbiology.

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

A. Horban, S. Ouwerkerk-Mahadevan, J. Sasadeusz, 2016, The Journal of antimicrobial chemotherapy.

Pooled week 96 results of the phase III DUET‐1 and DUET‐2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

B. Grinsztejn, P. Girard, J. Hartikainen, 2012, HIV medicine.

T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study

S. Roberts, S. Zeuzem, S. Pol, 2012 .

Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.

H. Masur, E. Freed, A. Ono, 2005, AIDS.

Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir

S. Zeuzem, C. Sarrazin, G. Lawyer, 2015, Antimicrobial Agents and Chemotherapy.

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

F. Negro, S. Zeuzem, S. Pol, 2013, Hepatology.

Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post‐discharge assessed by Respiratory Intensity and Impact Questionnaire

E. Walsh, A. Falsey, R. Osborne, 2021, Influenza and other respiratory viruses.

P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION

X. Forns, F. Nevens, D. Samuel, 2014 .

The impact of baseline characteristics on virologic response to etravirine: 48-week pooled analysis of DUET-1 and DUET-2

R. Haubrich, C. Katlama, P. Cahn, 2010 .

A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).

P. Ruane, R. Ryan, J. Witek, 2010, AIDS research and human retroviruses.

Pharmacoeconomics of etravirine

J. Mrus, M. Watson, J. Witek, 2010, Expert review of pharmacoeconomics & outcomes research.

O004 : On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II saturn study

X. Forns, M. Durlik, J. Calleja, 2015 .

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

E. Coakley, M. Haddad, J. Vingerhoets, 2011, AIDS Research and Human Retroviruses.

Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States

M. Gottlieb, J. Lalezari, J. Gathe, 2010, Journal of Acquired Immune Deficiency Syndromes.